Fortrea Holdings (FTRE) Liabilities from Discontinued Operations (2023 - 2024)
Fortrea Holdings' (FTRE) quarterly Liabilities from Discontinued Operations came in at $51.2 million in Q1 2024, down 2.48% quarter-over-quarter from $52.5 million in Q4 2023.
Powered by 
Analysis
Fortrea Holdings (FTRE) Liabilities from Discontinued Operations (2023 - 2024) Analysis & Trends
Fortrea Holdings (FTRE) has reported Liabilities from Discontinued Operations for 2 consecutive years, with $51.2 million the latest figure, recorded in Q1 2024.
- For the quarter ending Q1 2024, Liabilities from Discontinued Operations changed N/A year-over-year to $51.2 million; the trailing twelve-month figure through Mar 2024 stood at $51.2 million (changed N/A YoY), and the FY2023 full-year result was $52.5 million, changed N/A from the prior year.
- Liabilities from Discontinued Operations retreated to $51.2 million in Q1 2024 per FTRE's latest filing, from $52.5 million in the prior quarter.
- Across five years, Liabilities from Discontinued Operations topped out at $52.5 million in Q4 2023 and bottomed at $51.2 million in Q1 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.72 Bn | 42.64 Bn | 1.44 Bn |
| 2 | Medpace Holdings | 17.37 Bn | 16.87 Bn | 201.64 Mn |
| 3 | Icon | 13.65 Bn | 12.72 Bn | 479.29 Mn |
| 4 | Charles River Laboratories International | 13.13 Bn | 12.94 Bn | 452.07 Mn |
| 5 | Fortrea Holdings | 1.89 Bn | 1.72 Bn | 139.20 Mn |
| 6 | Evotec SE | 574.75 Mn | 148.87 Mn | - |
| 7 | Ginkgo Bioworks Holdings | 439.63 Mn | 355.09 Mn | 18.44 Mn |
| 8 | Champions Oncology | 69.43 Mn | 65.03 Mn | 7.70 Mn |
| 9 | MindWalk Holdings | 51.76 Mn | 46.29 Mn | 1.61 Mn |
| 10 | VivoSim Labs | 1.37 Mn | 1.37 Mn | - |